Full access to Entrepreneur for $5
Subscribe

Medpace (MEDP) Moves 3.3% Higher: Will This Strength Last?

Medpace (MEDP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions...

By
This story originally appeared on Zacks

Medpace (MEDP) shares rallied 3.3% in the last trading session to close at $193.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.7% gain over the past four weeks.

- Zacks

The stock scored a strong price increase driven by the optimism surrounding the company’s solid second-quarter 2021 results. Earnings per share exceeded the Zacks Consensus Estimate by 8.2% while revenues surpassed the estimate mark by 2.6%. The bullish full-year 2021 revenue guidance also raises investors’ confidence. For the full year, Medpace expects revenue growth in the range of 19.9% to 24.2% over 2020.

This provider of outsourced clinical development services is expected to post quarterly earnings of $1.07 per share in its upcoming report, which represents a year-over-year change of -5.3%. Revenues are expected to be $292.8 million, up 27.1% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Medpace, the consensus EPS estimate for the quarter has been revised 0.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on MEDP going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>



Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative. 

See Zacks’ Hottest Tech IPOs Now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research